Dopaminergic dysfunction is associated with IL-1β-dependent mood alterations in experimental autoimmune encephalomyelitis

Neurobiology of Disease

Volumn 74, Issue , 2014, Pages 347-358

  Gentile, Antonietta ^a,b   Fresegna, Diego ^a   Federici, Mauro ^a   Musella, Alessandra ^a,b   Rizzo, Francesca Romana ^a   Sepman, Helena ^a,b   Bullitta, Silvia ^a   De Vito, Francesca ^a   Haji, Nabila ^a   Rossi, Silvia ^a,b   Mercuri, Nicola B ^a,b   Usiello, Alessandro ^c,d   Mandolesi, Georgia ^a   Centonze, Diego ^a,b  

^a IRCCS FONDAZIONE SANTA LUCIA   (Italy)

^b UNIVERSITY OF ROME TOR VERGATA   (Italy)

^c CEINGE BIOTECNOLOGIE AVANZATE   (Italy)

^d SECOND UNIVERSITY OF NAPLES   (Italy)

Author keywords

Depression; Dopamine; EAE; IL 1 ; Striatum

Indexed keywords

DOPAMINE 1 RECEPTOR; DOPAMINE 2 RECEPTOR; INTERLEUKIN 1BETA; DOPAMINE; DRD2 PROTEIN, MOUSE; IL1B PROTEIN, MOUSE; MESSENGER RNA;

AMPEROMETRY; ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CATECHOLAMINE RELEASE; CATWALK GAIT ANALYSIS TEST; CONTROLLED STUDY; CORPUS STRIATUM; DEPRESSION; DOPAMINERGIC ACTIVITY; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; FEMALE; FORCED SWIM TEST; GRIP STRENGTH TEST; MOOD CHANGE; MOTOR DYSFUNCTION; MOTOR PERFORMANCE; MOUSE; MULTIPLE SCLEROSIS; NESTING; NEUROTRANSMISSION; NONHUMAN; PROTEIN EXPRESSION; PROTEIN FUNCTION; ROTAROD TEST; SIGNAL TRANSDUCTION; TAIL SUSPENSION TEST; ACUTE DISEASE; AMYGDALOID NUCLEUS; ANIMAL; ANTAGONISTS AND INHIBITORS; C57BL MOUSE; DRUG EFFECTS; HIPPOCAMPUS; IMMUNOLOGY; METABOLISM; PATHOLOGY; PHYSIOLOGY; PSYCHOLOGY; RANDOMIZATION; SEVERITY OF ILLNESS INDEX; SYNAPTIC TRANSMISSION;

ACUTE DISEASE; AMYGDALA; ANIMALS; CORPUS STRIATUM; DEPRESSION; DOPAMINE; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; FEMALE; HIPPOCAMPUS; INTERLEUKIN-1BETA; MICE, INBRED C57BL; MOTOR SKILLS; RANDOM ALLOCATION; RECEPTORS, DOPAMINE D1; RECEPTORS, DOPAMINE D2; RNA, MESSENGER; SEVERITY OF ILLNESS INDEX; SYNAPTIC TRANSMISSION;

EID: 84922597006     PISSN: 09699961     EISSN: 1095953X     Source Type: Journal    
DOI: 10.1016/j.nbd.2014.11.022     Document Type: Article

References (59)

1. Acharjee S., Nayani N., Tsutsui M., Hill M.N., Ousman S.S., Pittman Q.J. Altered cognitive-emotional behavior in early experimental autoimmune encephalitis-cytokine and hormonal correlates. Brain Behav. Immun. 2013, 33:164-172.
2. Aktas O., Zipp F. Regulation of self-reactive T cells by human immunoglobulins-implications for multiple sclerosis therapy. Curr. Pharm. Des. 2003, 9:245-256.
3. Aubert A. Sickness and behaviour in animals: a motivational perspective. Neurosci. Biobehav. Rev. 1999, 23:1029-1036.
4. Báez-Mendoza R., Schultz W. The role of the striatum in social behavior. Front. Neurosci. 2013, 7:233.
5. Benson C.A., Wong G., Tenorio G., Baker G.B., Kerr B.J. The MAO inhibitor phenelzine can improve functional outcomes in mice with established clinical signs in experimental autoimmune encephalomyelitis EAE. Behav. Brain Res. 2013, 252:302-311.
6. Bermel R.A., Innus M.D., Tjoa C.W., Bakshi R. Selective caudate atrophy in multiple sclerosis: a 3D MRI parcellation study. Neuroreport 2003, 14:335-339.
7. Blossom S.J., Doss J.C., Hennings L.J., Jernigan S., Melnyk S., James S.J. Developmental exposure to trichloroethylene promotes CD4+ T cell differentiation and hyperactivity in association with oxidative stress and neurobehavioral deficits in MRL+/+ mice. Toxicol. Appl. Pharmacol. 2008, 231:34-53.
8. Bluthé R.M., Beaudu C., Kelley K.W., Dantzer R. Differential effects of IL-1ra on sickness behavior and weight loss induced by IL-1 in rats. Brain Res. 1995, 677:171-176.
9. Boissonneault V., Filali M., Lessard M., Relton J., Wong G., Rivest S. Powerful beneficial effects of macrophage colony-stimulating factor on beta-amyloid deposition and cognitive impairment in Alzheimer's disease. Brain 2009, 132:1078-1092.
10. Brown R.F., Valpiani E.M., Tennant C.C., Dunn S.M., Sharrock M., Hodgkinson S., Pollard J.D. Longitudinal assessment of anxiety, depression, and fatigue in people with multiple sclerosis. Psychol. Psychother. 2009, 82:41-56.
11. Bulloch K., Hamburger R.N., Loy R. Nest-building behavior in two cerebellar mutant mice: staggerer and weaver. Behav. Neural Biol. 1982, 36:94-97.
12. Centonze D., Muzio L., Rossi S., Cavasinni F., De Chiara V., Bergami A., Musella A., D'Amelio M., Cavallucci V., Martorana A., et al. Inflammation triggers synaptic alteration and degeneration in experimental autoimmune encephalomyelitis. J. Neurosci. 2009, 29:3442-3452.
13. Chesselet M.F., Delfs J.M. Basal ganglia and movement disorders: an update. Trends Neurosci. 1996, 19:417-422.
14. Compston A., Coles A. Multiple sclerosis. Lancet 2008, 372:1502-1517.
15. Cosentino M., Zaffaroni M., Marino F., Bombelli R., Ferrari M., Rasini E., Lecchini S., Ghezzi A., Frigo G. Catecholamine production and tyrosine hydroxylase expression in peripheral blood mononuclear cells from multiple sclerosis patients: effect of cell stimulation and possible relevance for activation-induced apoptosis. J. Neuroimmunol. 2002, 133:233-240.
16. Cryan J.F., Mombereau C., Vassout A. The tail suspension test as a model for assessing antidepressant activity: review of pharmacological and genetic studies in mice. Neurosci. Biobehav. Rev. 2005, 29:571-625.
17. Dantzer R., O'Connor J.C., Freund G.G., Johnson R.W., Kelley K.W. From inflammation to sickness and depression: when the immune system subjugates the brain. Nat. Rev. Neurosci. 2008, 9:46-56.
18. David D.J., Renard C.E., Jolliet P., Hascoët M., Bourin M. Antidepressant-like effects in various mice strains in the forced swimming test. Psychopharmacology (Berl.) 2003, 166:373-382.
19. Feinstein A. Neuropsychiatric syndromes associated with multiple sclerosis. J. Neurol. 2007, 254:II73-II76.
20. Felger J.C., Miller A.H. Cytokine effects on the basal ganglia and dopamine function: the subcortical source of inflammatory malaise. Front. Neuroendocrinol. 2012, 33:315-327.
21. Filali M., Lalonde R., Rivest S. Cognitive and non-cognitive behaviors in an APPswe/PS1 bigenic model of Alzheimer's disease. Genes Brain Behav. 2009, 8:143-148.
22. Garcia-Ovejero D., González S., Paniagua-Torija B., Lima A., Molina-Holgado E., De Nicola A.F., Labombarda F. Progesterone reduces secondary damage, preserves white matter, and improves locomotor outcome after spinal cord contusion. J. Neurotrauma 2014, 31:857-871.
23. Geurts J.J., Barkhof F. Grey matter pathology in multiple sclerosis. Lancet Neurol. 2008, 7:841-851.
24. Grasselli G., Rossi S., Musella A., Gentile A., Loizzo S., Muzio L., Di Sanza C., Errico F., Musumeci G., Haji N., et al. Abnormal NMDA receptor function exacerbates experimental autoimmune encephalomyelitis. Br. J. Pharmacol. 2013, 168:502-517.
25. Haji N., Mandolesi G., Gentile A., Sacchetti L., Fresegna D., Rossi S., Musella A., Sepman H., Motta C., Studer V., et al. TNF-α-mediated anxiety in a mouse model of multiple sclerosis. Exp. Neurol. 2012, 237:296-303.
26. Hamers F.P., Koopmans G.C., Joosten E.A. CatWalk-assisted gait analysis in the assessment of spinal cord injury. J. Neurotrauma 2006, 23:537-548.
27. Imitola J., Chitnis T., Khoury S.J. Cytokines in multiple sclerosis: from bench to bedside. Pharmacol. Ther. 2005, 106:163-177.
28. Kawagoe K.T., Wightman R.M. Characterization of amperometry for in vivo measurement of dopamine dynamics in the rat brain. Talanta 1994, 41:865-874.
29. Koo J.W., Duman R.S. IL-1beta is an essential mediator of the antineurogenic and anhedonic effects of stress. Proc. Natl. Acad. Sci. U. S. A. 2008, 105:751-756.
30. Krishnan V., Nestler E.J. The molecular neurobiology of depression. Nature 2008, 455:894-902.
31. MacKenzie-Graham A., Rinek G.A., Avedisian A., Gold S.M., Frew A.J., Aguilar C., Lin D.R., Umeda E., Voskuhl R.R., Alger J.R. Cortical atrophy in experimental autoimmune encephalomyelitis: in vivo imaging. Neuroimage 2012, 60:95-104.
32. Mandolesi G., Musella A., Gentile A., Grasselli G., Haji N., Sepman H., Fresegna D., Bullitta S., De Vito F., Musumeci G., et al. Interleukin-1β alters glutamate transmission at purkinje cell synapses in a mouse model of multiple sclerosis. J. Neurosci. 2013, 33:12105-12121.
33. Markianos M., Koutsis G., Evangelopoulos M.E., Mandellos D., Karahalios G., Sfagos C. Relationship of CSF neurotransmitter metabolite levels to disease severity and disability in multiple sclerosis. J. Neurochem. 2009, 108:158-164.
34. Marrie R.A., Horwitz R., Cutter G., Tyry T., Campagnolo D., Vollmer T. The burden of mental comorbidity in multiple sclerosis: frequent, underdiagnosed, and undertreated. Mult. Scler. 2009, 15:385-392.
35. Meng C., Brandl F., Tahmasian M., Shao J., Manoliu A., Scherr M., Schwerthöffer D., Bäuml J., Förstl H., Zimmer C., et al. Aberrant topology of striatum's connectivity is associated with the number of episodes in depression. Brain 2014, 137:598-609.
36. Mercuri N.B., Bonci A., Calabresi P., Stefani A., Bernardi G. Properties of the hyperpolarization-activated cation current Ih in rat midbrain dopaminergic neurons. Eur. J. Neurosci. 1995, 7:462-469.
37. Mori F., Nisticò R., Mandolesi G., Piccinin S., Mango D., Kusayanagi H., Berretta N., Bergami A., Gentile A., Musella A., et al. Interleukin-1β promotes long-term potentiation in patients with multiple sclerosis. Neuromolecular Med. 2014, 16:38-51.
38. Murphy K.T., Chee A., Trieu J., Naim T., Lynch G.S. Importance of functional and metabolic impairments in the characterization of the C-26 murine model of cancer cachexia. Dis. Models Mech. 2012, 5:533-545.
39. Musgrave T., Benson C., Wong G., Browne I., Tenorio G., Rauw G., Baker G.B., Kerr B.J. The MAO inhibitor phenelzine improves functional outcomes in mice with experimental autoimmune encephalomyelitis (EAE). Brain Behav. Immun. 2011, 25:1677-1688.
40. Musgrave T., Tenorio G., Rauw G., Baker G.B., Kerr B.J. Tissue concentration changes of amino acids and biogenic amines in the central nervous system of mice with experimental autoimmune encephalomyelitis (EAE). Neurochem. Int. 2011, 59:28-38.
41. Nakano K., Higashi T., Hashimoto K., Takagi R., Tanaka Y., Matsushita S. Antagonizing dopamine D1-like receptor inhibits Th17 cell differentiation: preventive and therapeutic effects on experimental autoimmune encephalomyelitis. Biochem. Biophys. Res. Commun. 2008, 373:286-291.
42. Nisticò R., Mango D., Mandolesi G., Piccinin S., Berretta N., Pignatelli M., Feligioni M., Musella A., Gentile A., Mori F., et al. Inflammation subverts hippocampal synaptic plasticity in experimental multiple sclerosis. PLoS One 2013, 8:e54666.
43. Norden D.M., Bicer S., Clark Y., Jing R., Henry C.J., Wold L.E., Reiser P.J., Godbout J.P., McCarthy D.O. Tumor growth increases neuroinflammation, fatigue and depressive-like behavior prior to alterations in muscle function. Brain Behav. Immun. 2014, 10.1016/j.bbi.2014.07.013.
44. Peruga I., Hartwig S., Thone J., Hovemann B., Gold R., Juckel G., Linker R.A. Inflammation modulates anxiety in an animal model of multiple sclerosis. Behav. Brain Res. 2011, 220:20-29.
45. Petit-Demouliere B., Chenu F., Bourin M. Forced swimming test in mice: a review of antidepressant activity. Psychopharmacology (Berl.) 2005, 177:245-255.
46. Pollak Y., Orion E., Goshen I., Ovadia H., Yirmiya R. Experimental autoimmune encephalomyelitis-associated behavioral syndrome as a model of 'depression due to multiple sclerosis'. Brain Behav. Immun. 2002, 16:533-543.
47. Pollak Y., Ovadia H., Goshen I., Gurevich R., Monsa K., Avitsur R., Yirmiya R. Behavioral aspects of experimental autoimmune encephalomyelitis. J. Neuroimmunol. 2000, 104:31-36.
48. Pollak Y., Ovadia H., Orion E., Yirmiya R. The EAE-associated behavioral syndrome: II. Modulation by anti-inflammatory treatments. J. Neuroimmunol. 2003, 137:100-108.
49. Ripoll N., David D.J., Dailly E., Hascoët M., Bourin M. Antidepressant-like effects in various mice strains in the tail suspension test. Behav. Brain Res. 2003, 143:193-200.
50. Rossi S., Muzio L., De Chiara V., Grasselli G., Musella A., Musumeci G., Mandolesi G., De Ceglia R., Maida S., Biffi E., Pedrocchi A., Menegon A., Bernardi G., Furlan R., Martino G., Centonze D. Impaired striatal GABA transmission in experimental autoimmune encephalomyelitis. Brain Behav. Immun. 2010, 25:947-956.
51. Rossi S., Furlan R., De Chiara V., Motta C., Studer V., Mori F., Musella A., Bergami A., Muzio L., Bernardi G., et al. Interleukin-1β causes synaptic hyperexcitability in multiple sclerosis. Ann. Neurol. 2012, 71:76-83.
52. Sager T.N., Kirchhoff J., Mørk A., Van Beek J., Thirstrup K., Didriksen M., Lauridsen J.B. Nest building performance following MPTP toxicity in mice. Behav. Brain Res. 2010, 208:444-449.
53. Scarponi M., Bernardi G., Mercuri N.B. Electrophysiological evidence for a reciprocal interaction between amphetamine and cocaine-related drugs on rat midbrain dopaminergic neurons. Eur. J. Neurosci. 1999, 11:593-598.
54. Suh Y., Motl R.W., Mohr D.C. Physical activity, disability, and mood in the early stage of multiple sclerosis. Disabil. Health J. 2010, 3:93-98.
55. Surmeier D.J., Ding J., Day M., Wang Z., Shen W. D1 and D2 dopamine-receptor modulation of striatal glutamatergic signaling in striatal medium spiny neurons. Trends Neurosci. 2007, 30:228-235.
56. Svenningsson P., Nishi A., Fisone G., Girault J.A., Nairn A.C., Greengard P. DARPP-32: an integrator of neurotransmission. Annu. Rev. Pharmacol. Toxicol. 2004, 44:269-296.
57. Takao K., Kobayashi K., Hagihara H., Ohira K., Shoji H., Hattori S., Koshimizu H., Umemori J., Toyama K., Nakamura H.K., et al. Deficiency of schnurri-2, an MHC enhancer binding protein, induces mild chronic inflammation in the brain and confers molecular, neuronal, and behavioral phenotypes related to schizophrenia. Neuropsychopharmacology 2013, 38:1409-1425.
58. Tao G., Datta S., He R., Nelson F., Wolinsky J.S., Narayana P.A. Deep gray matter atrophy in multiple sclerosis: a tensor based morphometry. J. Neurol. Sci. 2009, 282(1-2):39-46.
59. Zhu C.B., Blakely R.D., Hewlett W.A. The proinflammatory cytokines interleukin-1beta and tumor necrosis factor-alpha activate serotonin transporters. Neuropsychopharmacology 2006, 31:2121-2131.